CClinicalTrials.gg
Status unknownNCT04219683Updated Jan 7, 2020

Mandibular Vertical Height Augmentation in Segmental Defects Using Combined Vascularized and Non-Vascularized Fibula Flap

An interventional study of Mandibular vertical height augmentation in segmental defects using combined vascularized and non-vascularized fibula flap in Mandibular Reconstruction Using Free Fibula Flap, sponsored by Cairo University. Status unknown. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-01-07.

Sponsored by Cairo University · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Jan 2020), so the status shown — last known as Not yet recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
7
Allocation
Not applicable
Ages
18 Years to 60 Years
Sex
All
01

Study summary

Segmental mandibulectomy, often employed for resection of a tumour, and occasionally for trauma, osteoradionecrosis, or osteomyelitis, adversely affects patient's quality of life (QoL) to a varying degree. It inflicts a significant defect in the head and neck region, impacting on facial appearance, and the functions of speech, malocclusion, mastication, swallowing, and health-related QoL. Mandible resection thus creates a significant impact on a patient's life, both aesthetically as well as functionally.

Restoration of the defects following resection of any part of the mandible presents a challenging problem for reconstructive surgeons. Since the introduction of fibula free flap (FFF) by Taylor in 1975, it has become the most popular choice for mandible reconstruction. Hidalgo popularized the FFF, and reported on its versatility with satisfactory outcomes. The utility and techniques of free flap mandible reconstruction have advanced in the past 2 decades, with success rate up from 82.6% to 100%. As the longest bone segment available for reconstructive purpose, FFF is known for its wide variety of applications, following mandible resection, including angle-to-angle reconstruction.

The fibula-free flap is currently considered the most popular, 'the gold standard and the workhorse flap' for mandibular reconstruction.

However, because of the limited diameter of the fibula flap compared with the height of the mandible, vertical distance between the reconstructed segment and the occlusal plane can be substantial. This is a particular problem in the dentate mandible, especially when rehabilitation with dental implants or an implant-borne denture is contemplated. Insufficient bone height leads to overloading of osteointegrated implants and endangers the longevity of the prosthetic restoration. Insufficient bone height and poor soft tissue overlying the bone flap also create an unfavourable environment for the tissue-borne prosthesis.

Such issues are particularly acute in patients with intact alveolar bone and dentition at healthy sites. The double-barrel technique, distraction osteogenesis, non-vascularized bone grafts, and guided-bone regeneration have all been used to resolve this. The double-barrel technique is a good method, but drawbacks include excess height of the neomandible and the considerable time required to contour and adapt the upper barrel. Distraction osteogenesis is a valuable and predictable treatment option; however, its wide application is limited by complexity of the surgery and the need for additional secondary surgery.

To Overcome these challenges the investigators design a technique for mandibular reconstruction where free vascularized fibula flap is splitted and non-vascularized fibula graft is harvest from same leg and is placed between two splitted parts of free fibula flap to increase vertical height of fibula.

02

Conditions studied

  • Mandibular Reconstruction Using Free Fibula Flap

Keywords

  • free fibula flap - Mandibular reconstruction - Segmental Defects
03

In context

Lead sponsor

Cairo University is the lead sponsor of 4,780 studies on the registry; 1,427 are open to participants now.

Of its 36 completed or terminated interventional studies of FDA-regulated products, 5 (14%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Patient who require mandibular resection due to tumor, trauma, osteomyelitis or osteoradionecrosis.
  • Patient with Mandibular defect >9 cm.

Exclusion criteria

Exclusion Criteria:

  • Patients with systemic condition counteracting with the surgical procedure.
  • Patients with conditions contraindicating fibular flap.
  • Patients with extensive defects of the mandible where the length of the harvested fibula flap would not allow for simultaneous ipsilateral harvesting of a non-vascularized segment.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
7 participants (estimated)

Study arms

  • Experimental
    Patient with resected Mandible

    Patient with resected mandible who is candidate for free fibula flap

    Procedure: Mandibular vertical height augmentation in segmental defects using combined vascularized and non-vascularized fibula flap

Interventions

  • ProcedureMandibular vertical height augmentation in segmental defects using combined vascularized and non-vascularized fibula flap

    Using Free Fibula Flap for reconstruction of mandibular segemental defect

06

What researchers measure

Primary outcomes

  1. Height of mandible

    Amount of vertical height gain (Mandibular augmentation) using Multi-slice CT Scan - Measured in millimeters

    Time frame: one year

Secondary outcomes

  1. Patient Satisfaction: Visual analogue Scale

    Patient Satisfaction using Visual analogue Scale - Scale from 0-10

    Time frame: One year

07

Study locations

No study locations are listed for this record.

08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 7, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04219683
Lead sponsor
Cairo University
Responsible party
Ahmed Mohamed Magdy AbdelMoaz (Resident in Oral and Maxillofacial Surgery Department faculty of dentistry- Cairo University, Cairo University) — Principal investigator
First posted
Jan 7, 2020
Start date
Feb 1, 2020 (estimated)
Primary completion
Feb 1, 2021 (estimated)
Completion
Feb 1, 2021 (estimated)
Last update
Jan 7, 2020

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion